Browsing Category
Pharma Industry News
4743 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
MiNK Therapeutics surges over 700% after testicular cancer remission data fuels iNKT therapy optimism
MiNK Therapeutics stock explodes 730% after iNKT cell therapy shows full remission in metastatic cancer. Read what’s driving investor frenzy.
Which biotech companies are developing next-gen GLP-1 alternatives—and can they compete with Novo Nordisk and Eli Lilly by 2030?
Discover how biotech players like Viking, Structure, and Altimmune are developing next-gen GLP-1 drugs to challenge obesity leaders Novo Nordisk and Eli Lilly. Read more.
Glenmark Pharmaceuticals surges 10% after AbbVie licensing deal boosts ISB 2001 global reach
Glenmark Pharmaceuticals stock jumps 10% after announcing ISB 2001 licensing deal with AbbVie; find out what this could mean for its oncology ambitions.
Alterity Therapeutics stock surges 33% after ATH434 momentum and FDA fast track designation
Alterity Therapeutics surged 33% after highlighting ATH434’s Phase 2 gains and FDA Fast Track status. Find out why investors are piling in now.
Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit
Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline.
Tonix Pharmaceuticals (NASDAQ: TNXP) surges 9.5% as fibromyalgia data and vaccine platform boost investor confidence
Tonix Pharmaceuticals stock surged 9.5% after new fibromyalgia and mpox vaccine data. Find out what’s driving investor optimism and what comes next.
Ultragenyx stock plummets 25% after Phase 3 OI trial continues without early stop
Ultragenyx stock plunged 25% as the UX143 Phase 3 trial for osteogenesis imperfecta proceeds without early stop. Find out what this means for investors.
ProKidney (NASDAQ: PROK) stock surges over 22% after Phase 2 REGEN-007 trial shows strong kidney function stabilization
Find out why ProKidney stock soared 22% after new Phase 2 data on rilparencel in chronic kidney disease patients. Analysts see potential FDA fast-track.
Can oral GLP-1 pills match injected options in efficacy and patient adherence? What’s next for Wegovy and Rybelsus
Can oral GLP-1 drugs like Wegovy and orforglipron match injectables in weight loss and adherence? Discover what’s next in chronic obesity treatment.
Can Merck turn Ohtuvayre into a global COPD blockbuster? A look at pricing, access, and lifecycle strategy
Can Merck scale Ohtuvayre into a global COPD blockbuster? Explore its pricing strategy, global access plans, and lifecycle ambitions in this in-depth analysis.